MRK - Merck & Co., Inc.
| Previous close | 79.83 |
| Open | 79.77 |
| Bid | 0.00 x 1200 |
| Ask | 81.00 x 800 |
| Day's range | 79.77 - 80.86 |
| 52-week range | 52.83 - 80.86 |
| Volume | 7,955,621 |
| Avg. volume | 12,938,998 |
| Market cap | 210.033B |
| Beta (3Y monthly) | 0.38 |
| PE ratio (TTM) | 34.81 |
| EPS (TTM) | 2.32 |
| Earnings date | 30 Apr 2019 |
| Forward dividend & yield | 2.20 (2.78%) |
| Ex-dividend date | 2019-03-14 |
| 1y target est | 83.02 |
- Zacks•yesterday
Merck to Buy Immunotherapy Developer Immune Design for $300M
Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
- Zacks•2 days ago
What's in the Cards for Perrigo (PRGO) This Earnings Season?
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
- Zacks•2 days ago
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
- Zacks•2 days ago
Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review
The index endured a holiday-shortened but volatile week.
- GlobeNewswire•3 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders
NEW YORK, Feb. 21, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Immune Design Corp. (“Immune Design”.
- Zacks•3 days ago
Merck Gets Priority Review for Keytruda in Third-Line SCLC
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
- Business Wire•3 days ago
Merck to Acquire Immune Design
Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer
- Zacks•4 days ago
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks•4 days ago
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study
Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
- Zacks•4 days ago
Intercept Reports Positive Top-Line Data for NASH, Shares Up
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
- GlobeNewswire•4 days ago
New Research: Key Drivers of Growth for DISH Network, Avon Products, Merck & Co., Laredo Petroleum, Health Insurance Innovations, and Bruker — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•4 days ago
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer (SCLC)
Marks First Application for KEYTRUDA in SCLC
- Business Wire•4 days ago
Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma
Merck , known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival and progression-free survival ...
- Zacks•5 days ago
Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why
Merck's (MRK) stock is up 45.2% in the past year. Here are reasons for the same.
- Motley Fool•5 days ago
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
A drug that disappointed in 2018 will get an unexpected dance at the big ball.
- Business Wire•5 days ago
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
U.S. Approval Based on Significant Recurrence-Free Survival Benefit Demonstrated with KEYTRUDA in Phase 3 EORTC1325/KEYNOTE-054 Trial
- Zacks•6 days ago
Merck Gets Priority Review for Keytruda Combo in Kidney Cancer
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
- Reuters•7 days ago
Merck, Pfizer drug combo extends kidney cancer survival -study
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released interim data from the trial, saying the combination reduced the risk of death by 47 percent compared with Sutent.
- Business Wire•7 days ago
KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)
Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium and Published in the New England Journal of Medicine Also Showed Risk o
Market Realist•8 days agoWhat Are Merck’s Key Growth Drivers for 2019?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth driversOn its fourth-quarter earnings conference call, Merck & Co. (MRK) highlighted its oncology, vaccines, hospital and specialty care, and animal
Market Realist•9 days agoComparing Dividends and Tax Rates for MRK and GSK in 2019
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect
- Market Realist•9 days ago
Merck or GlaxoSmithKline: Which Is Controlling Expenses Better?
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Expenses guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for a low- to mid-single-digit YoY (year-over-year) rise
- Business Wire•9 days ago
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma
Application Based on Overall Survival and Progression-Free Survival Data from Phase 3 KEYNOTE-426 Trial
- GlobeNewswire•9 days ago
Cerecor Announces CERC-301 Granted U.S. Patent
Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,202,363 ("the ‘363 patent") on Feb. 12, 2019, which is directed to CERC‑301, an oral, NR2B-specific, NMDA receptor antagonist. CERC-301 is a selective NR2B-specific NMDA receptor antagonist with a unique mechanism of action tested in 375 subjects to date. CERC-301 is being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy and Pure Autonomic Failure.
- Zacks•9 days ago
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat
Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
